PM&R
Volume 2, Issue 4 , Pages 282-284, April 2010

Safety Considerations in the Use of Botulinum Toxins in Children With Cerebral Palsy

  • Susan D. Apkon, MD

      Affiliations

    • Department of Rehabilitation Medicine, University of Washington; and Department of Rehabilitation Medicine, Seattle Children's, M/S W-9847, PO Box 5371, Seattle, WA
    • Corresponding Author InformationAddress correspondence to S.D.A.
  • ,
  • Danielle Cassidy, PharmD

      Affiliations

    • Investigational Drug Services & Anticoagulation Clinical Pharmacist, The Children's Hospital, Denver, CO

Received 22 December 2009; accepted 17 February 2010.

The use of botulinum toxins to decrease spasticity in children with cerebral palsy has become standard of care during the past decade. In 2008 reports of severe adverse events, including death, were reported in children who received injections of these medications. The following discussion focuses on the background of these reports, the response of the U.S. Food and Drug Administration, as well as the safety profile and pharmacokinetics of botulinum toxins. Finally, the authors will offer their perspective on the safe use of botulinum toxins.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 
  •  Disclosure: nothing to disclose
  •  Disclosure: nothing to disclose

PII: S1934-1482(10)00131-0

doi:10.1016/j.pmrj.2010.02.006

PM&R
Volume 2, Issue 4 , Pages 282-284, April 2010